Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This study will test the hypothesis that early use of combination therapy with dapagliflozin and metformin will provide good glycemic control with low glycemic variability and without hypoglycemic episodes, and will be better tolerated than up-titration of metformin monotherapy. The study will also correlate these benefits with glycated hemoglobin.
Epistemonikos ID: 463fcbc90151f7a0e429ff6d4808e0f9883d3ffa
First added on: May 12, 2024